Selling an Orthopedic Practice in 2026: Multiples, Named Buyers, and the MSO Playbook
Quick Answer
A US orthopedic practice in 2026 typically sells for roughly 5x to 13x EBITDA, varying by subspecialty mix (general ortho vs. spine vs. sports vs. joint replacement), ASC ownership, ancillary services (PT, imaging, DME), and platform scale. By profile: a single-MD orthopedic practice at $500k-1.5M EBITDA goes 5x-7x; a multi-MD single-site or 2-3 location practice ($1.5-5M EBITDA) goes 6x-9x; a small regional ortho group with ASC ownership (5-15 providers, $3-10M EBITDA) goes 7x-10x; a mid-size platform ($10-30M EBITDA, multi-site, ASC + PT + imaging integrated) goes 9x-12x; a premium scale platform ($30M+ EBITDA, multi-state, full ancillary suite, named commercial in-network) reaches 10x-13x+. Active buyers include US Orthopaedic Partners (Welsh Carson Anderson & Stowe, multi-state platform), Healthcare Outcomes Performance Company / HOPCo (PE-backed, multi-state with payer-arrangement focus), Resurgens Orthopaedics (Atlanta-anchored, ortho + pain), Spire Orthopedic Partners (PE-backed Northeast), OrthoLazer (PE-backed laser-MIS focus), OrthoConnecticut, OrthoCarolina (large independent), OrthoVirginia, plus PE sponsors (Welsh Carson Anderson & Stowe, Audax Group, Frazier Healthcare Partners, NMS Capital, Webster Equity Partners). The biggest multiple drivers are ASC ownership (Stark-compliant; ASC is the major multiple-builder for ortho), ancillary services (in-office PT, imaging, DME, infusion), subspecialty mix (joint replacement and spine premium), commercial payer mix, and value-based-care contract participation (BPCI Advanced, Medicare bundles). Buyer-paid M&A advisory (CT Strategic Partners) costs the seller nothing.
If you own a US orthopedic practice in 2026, the M&A market is one of the most active physician-services consolidations. US Orthopaedic Partners (Welsh Carson Anderson & Stowe), HOPCo (PE-backed), Resurgens Orthopaedics, and Spire Orthopedic Partners lead PE-backed roll-ups. OrthoCarolina and OrthoVirginia are major independents. PE sponsors continue regional consolidation driven by ASC ownership economics, ancillary integration, and value-based-care opportunity.
What the asset is worth depends on three things: (1) ASC ownership and Stark-compliant structure, (2) ancillary services integration (in-office PT, imaging, DME), and (3) subspecialty mix plus commercial payer mix. This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.
What this guide covers
- Orthopedic multiples 2026: 5x-7x for single-MD, 6x-9x for multi-MD, 7x-10x for small regional with ASC, 9x-12x for mid-size platforms, 10x-13x+ for premium scale with full ancillary + named in-network contracts.
- Active buyers: US Orthopaedic Partners (Welsh Carson Anderson & Stowe), HOPCo (PE-backed), Resurgens Orthopaedics, Spire Orthopedic Partners (PE-backed Northeast), OrthoLazer, OrthoCarolina, OrthoVirginia.
- PE sponsor activity: Welsh Carson Anderson & Stowe, Audax Group, Frazier Healthcare Partners, NMS Capital, Webster Equity Partners.
- Multiple drivers: ASC ownership (Stark-compliant, the major multiple-builder), ancillary services (in-office PT, imaging, DME, infusion), subspecialty mix (joint + spine premium), commercial payer mix, value-based-care (BPCI Advanced, Medicare bundles).
- Things that compress: no ASC ownership, weak ancillary integration, owner-MD dependence, Medicare-heavy payer mix, single-state, Stark/anti-kickback exposure on ASC arrangements.
- Sellers pay nothing on CT Strategic Partners’ buyer-paid advisory.
Named M&A transactions (2021-2025)
| Target | Buyer | Year | What it tells us |
|---|---|---|---|
| US Orthopaedic Partners continued growth | Welsh Carson Anderson & Stowe | 2022-2025 | PE-backed multi-state ortho platform continues regional consolidation. |
| HOPCo regional acquisitions | Healthcare Outcomes Performance Company (PE-backed) | 2022-2025 | Value-based-care-focused ortho platform continues growth. |
| Spire Orthopedic Partners expansion | PE-backed | 2022-2025 | Northeast ortho platform continues regional rollups. |
| Resurgens Orthopaedics continued growth | PE-backed | 2022-2025 | Atlanta-anchored ortho + pain platform continues regional expansion. |
| Multiple regional ortho tuck-ins | Various PE platforms | 2022-2025 | PE sponsors continue selective regional ortho consolidation. |
The named buyer landscape
PE-backed national orthopedic MSOs
- US Orthopaedic Partners (Welsh Carson Anderson & Stowe) — multi-state ortho platform.
- Healthcare Outcomes Performance Company / HOPCo (PE-backed) — multi-state platform with payer-arrangement and value-based-care focus.
- Spire Orthopedic Partners (PE-backed) — Northeast.
- Resurgens Orthopaedics — Atlanta-anchored ortho + pain.
- OrthoLazer (PE-backed) — laser MIS focus.
Large independent ortho groups
- OrthoCarolina, OrthoVirginia, OrthoIndy, OrthoTennessee, Rothman Orthopedics.
PE sponsors active in this space
- Welsh Carson Anderson & Stowe (US Orthopaedic Partners), Audax Group, Frazier Healthcare Partners, NMS Capital, Webster Equity Partners, plus multiple healthcare-services PE funds.
What each buyer will pay for vs. what they reject
- Will pay premium for: ASC ownership with Stark-compliant structure (group practice exception, in-office ancillary services exception), ancillary services integration (in-office PT, imaging, DME, infusion), subspecialty mix (joint replacement, spine, sports medicine, hand surgery, foot/ankle), commercial payer mix 55%+, value-based-care participation (BPCI Advanced, Medicare bundled payments, commercial ortho bundles), modern EMR (eClinicalWorks, Athenahealth, Modernizing Medicine EMA-Ortho).
- Will compress or reject: no ASC ownership, weak ancillary integration, owner-MD dependence, Medicare-heavy payer mix above 60%, single-state operations, Stark or anti-kickback exposure on ASC arrangements, legacy EMR.
The operator-level KPI playbook buyers will diligence
Subspecialty and case mix
- Subspecialty mix: General ortho, joint replacement (hip + knee), spine, sports medicine, hand, foot/ankle, pediatric, oncology.
- Joint replacement volume (hip + knee): Premium high-revenue procedures.
- Spine surgery volume.
- Average revenue per case by type.
ASC ownership and ancillary
- ASC ownership: Wholly-owned vs. JV with Surgery Partners / USPI / hospital. Stark-compliant structure.
- In-office PT, imaging, DME, infusion revenue.
- Total ancillary as % of revenue.
Payer mix
- Commercial percentage: 55%+ is platform benchmark.
- Medicare percentage: 25-40% typical.
- Workers’-comp percentage.
- Value-based-care participation: BPCI Advanced, commercial ortho bundles.
Provider bench
- MD count by subspecialty.
- PA/ATC scaling.
- Provider productivity (encounters/day, surgical cases/week).
- Equity-rollover expectations (PE-MSO ortho deals typically 25-45% rollover).
Dangers and traps
1. Stark and anti-kickback exposure on ASC arrangements
Physician-owned ASC must be Stark-compliant under group practice / in-office ancillary services exception.
2. No ASC ownership
ASC is the major multiple-builder for orthopedic practices.
3. Weak ancillary integration
PT, imaging, DME, infusion integration adds 1-3 turns EBITDA multiple.
4. Owner-MD dependence
Build the MD bench.
5. Medicare-heavy payer mix
Above 60% Medicare compresses.
6. Value-based-care exposure mismatch
BPCI Advanced and commercial ortho bundles are growing; document participation.
7. CON state exposure
Some states require Certificate of Need for ASC; document position.
8. Equity rollover expectations
PE-MSO ortho deals typically 25-45% equity rollover.
Our POV in 2026
Orthopedic M&A is one of the most active physician-services consolidations. US Orthopaedic Partners (Welsh Carson Anderson & Stowe) and HOPCo lead PE-backed national platforms. ASC ownership is the major multiple-builder. Value-based-care (BPCI Advanced, commercial ortho bundles) is the structural tailwind.
The right time to prepare is 12-18 months before going to market — structure Stark-compliant ASC, integrate ancillaries, develop value-based-care positioning, build provider bench.
Preparing your business for sale: 12-18 months out
- Get multi-year audited financials.
- Structure Stark-compliant ASC arrangements.
- Build ancillary services (in-office PT, imaging, DME, infusion).
- Develop value-based-care contract participation.
- Confirm commercial in-network status.
- Build the MD/PA provider bench.
- Modernize EMR (eClinicalWorks, Athenahealth, Modernizing Medicine EMA-Ortho).
- Document add-backs.
- Run a competitive process. US Orthopaedic Partners (Welsh Carson Anderson & Stowe), HOPCo, Resurgens, Spire Orthopedic Partners, OrthoLazer, plus PE sponsors directly (Welsh Carson Anderson & Stowe, Audax Group, Frazier Healthcare Partners, NMS Capital, Webster Equity Partners).
About the Author
Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch
Free, No Email Required
Get a personalized valuation in 90 seconds
Answer six quick questions and we’ll give you a sector-adjusted EBITDA multiple range plus the specific factors driving your number up or down.
Open the Valuation Tool →The five pillars of how CT Acquisitions works
Buyer pays our fee. Founders never write a check.
No engagement letter. No upfront cost. No exclusivity contract.
Search funders, family offices, lower-middle-market PE, strategics.
Confidential introductions to the right buyers. No bidding war.
Not 9-12 months. Not 18 months. Months, not years.
No Pitch · No Pressure
Ready to start a confidential conversation?
Tell us about your business. We’ll tell you what it’s likely worth, whether we have qualified buyers in our network, and what the next 60-120 days could look like. No engagement letter. No retainer. Walk at any time.
Start a Confidential Conversation →Frequently asked questions
What is the typical multiple for an orthopedic practice in 2026?
Single-MD orthopedic practices ($500k-1.5M EBITDA) typically sell at 5x-7x EBITDA. Multi-MD single-site or 2-3 location practices ($1.5-5M EBITDA) go 6x-9x. Small regional ortho groups with ASC ownership ($3-10M EBITDA) go 7x-10x. Mid-size platforms ($10-30M EBITDA, multi-site, ASC + PT + imaging integrated) go 9x-12x. Premium scale platforms ($30M+ EBITDA, multi-state, full ancillary suite, named commercial in-network) reach 10x-13x+.
Who are the active buyers of orthopedic practices right now?
PE-backed national MSOs: US Orthopaedic Partners (Welsh Carson Anderson & Stowe), Healthcare Outcomes Performance Company / HOPCo (PE-backed), Spire Orthopedic Partners (PE-backed Northeast), Resurgens Orthopaedics, OrthoLazer. Large independents: OrthoCarolina, OrthoVirginia, OrthoIndy, Rothman Orthopedics. PE sponsors: Welsh Carson Anderson & Stowe, Audax Group, Frazier Healthcare Partners, NMS Capital, Webster Equity Partners.
What hurts an orthopedic practice’s valuation most?
No ASC ownership (ASC is the major multiple-builder), Stark or anti-kickback exposure on ASC arrangements, weak ancillary integration, owner-MD dependence, Medicare-heavy payer mix above 60%, single-state operations, weak commercial in-network status, legacy EMR.
Why is ASC ownership so important for orthopedic practices?
ASC (ambulatory surgery center) ownership provides material additional EBITDA from facility fees on surgical cases (especially joint replacement, spine, sports medicine), and creates a buyer-attractive surgical platform. Stark-compliant ASC structures (group practice exception, in-office ancillary services exception) are essential. ASCs add 2-4 turns of EBITDA multiple over no-ASC practices.
What is the value-based-care opportunity in orthopedics?
BPCI Advanced (Medicare Bundled Payments for Care Improvement) and commercial orthopedic bundles (joint replacement, spine) reward operators for delivering total episode-of-care at fixed price. Orthopedic platforms with value-based-care participation capture upside and demonstrate the scale + analytics required for premium multiples.
Do I have to pay a broker fee?
No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing.
How long does it take to sell an orthopedic practice?
Typical process 5-9 months. Add 12-18 months of preparation work before going to market.
When should I start preparing if I plan to sell in 2027 or 2028?
12-18 months before going to market. Highest-leverage work: structure Stark-compliant ASC, integrate ancillaries (PT, imaging, DME, infusion), develop value-based-care positioning, build provider bench.
Related research
- How to sell a pain management practice
- How to sell a physical therapy practice
- How to sell an imaging center
- How to sell a DME business
- How to sell an urgent care center
- How to sell an infusion therapy business
- How to sell an ophthalmology practice
- Healthcare business valuation
- Which industries is PE buying most in 2026
- Business broker alternative